2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T614,This study aimed to compare the efficacy and safety of an initial 12 mg versus 6 mg adenosine dose for sinus rhythm conversion in patients presenting with supraventricular tachycardia (SVT) in the emergency department (ED). This prospective observational study was conducted between February 2025 and January 2026. Adult patients (≥ 18 years) presenting to the ED with hemodynamically stable SVT confirmed by 12-lead electrocardiography (ECG) were included. Patients were categorized into two groups according to the initial adenosine dose administered (6 mg vs. 12 mg). To address potential selection bias, 1:1 propensity score matching (PSM) was performed. The primary outcome was successful first-dose sinus rhythm conversion. Secondary outcomes included adenosine-related adverse effects and SVT recurrence during the ED stay. A total of 142 patients were analyzed (n = 71 per group). First-dose conversion was significantly higher with 12 mg compared with 6 mg (83.1% vs. 52.1%). In the PSM cohort (n = 104), the 12 mg dose maintained its superior efficacy (82.7% vs. 53.8%). The PSM-adjusted odds ratio for successful conversion was 4.12 (95% confidence interval [CI]: 1.85-9.14), with a number needed to treat (NNT) of 3.8 (95% CI: 2.5-8.3). SVT recurrence was numerically lower in the 12 mg group (1.4% vs. 9.9%). Adverse effects were similar between groups. An initial 12 mg adenosine dose was associated with higher first-dose sinus rhythm conversion than 6 mg, while adverse effects were similar between groups.31:T95f,ABSTRACT Objectives This study aimed to compare the efficacy and safety of an initial 12 mg versus 6 mg adenosine dose for sinus rhythm conversion in patients presenting with supraventricular tachycardia (SVT) in the emergency department (ED). Methods This prospective observational study was conducted between February 2025 and January 2026. Adult patients (≥ 18 years) presenting to the ED with hemodynamically stable SVT confirmed by 12‐lead electrocardiography (ECG) were included. Patients were categorized into two groups according to the initial adenosine dose administered (6 mg vs. 12 mg). To address potential selection bias, 1:1 propensity score matching (PSM) was performed. The primary outcome was successful first‐dose sinus rhythm conversion. Secondary outcomes included adenosine‐related adverse effects and SVT recurrence during the ED stay. Results A total of 142 patients were analyzed ( n = 71 per group). First‐dose conversion was significantly higher with 12 mg compared with 6 mg (83.1% vs. 52.1%). In the PSM cohort ( n = 104), the 12 mg dose maintained its superior efficacy (82.7% vs. 53.8%). The PSM‐adjusted odds ratio for successful conversion was 4.12 (95% confidence interval [CI]: 1.85–9.14), with a number needed to treat (NNT) of 3.8 (95% CI: 2.5–8.3). SVT recurrence was numerically lower in the 12 mg group (1.4% vs. 9.9%). Adverse effects were similar between groups. Conclusions An initial 12 mg adenosine dose was associated with higher first‐dose sinus rhythm conversion than 6 mg, while adverse effects were similar between groups. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Antiarrhythmic: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Antiarrhythmic (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Antiarrhythmic\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Antiarrhythmic\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Antiarrhythmic\"}]}}"}}]],["$","$L2f",null,{"title":"Antiarrhythmic: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Antiarrhythmic — concise summaries and practical next steps.","papers":[{"doi":"10.1093/fampra/cmag048","pmid":"42400941","title":"Assessing the risk of drug-induced corrected QT interval prolongation in primary care","journal_title":"Family Practice","journal_issn":"0263-2136","published_at":"2026-07-04T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13332750/","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-10T13:25:32.097Z","updated_at":"2026-07-10T13:25:32.097Z","tags":[{"paper_doi":"10.1093/fampra/cmag048","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"category","value":"Primary Health Care","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"condition","value":"Drug-Induced QT Prolongation","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"condition","value":"Torsades de Pointes","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"generic","value":"amiodarone","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"generic","value":"aripiprazole","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"generic","value":"citalopram","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"generic","value":"escitalopram","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"generic","value":"mirtazapine","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"generic","value":"nortriptyline","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"generic","value":"venlafaxine","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"modality","value":"Antiarrhythmic","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"modality","value":"Antidepressant","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"modality","value":"Antipsychotic","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"sample_size","value":"n=486","value_numeric":486},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"study_design","value":"Retrospective Chart Audit","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"warning","value":"Cases and controls differed in age and sex distribution, which may confound baseline QTc comparisons despite the non-significant P-value reported.","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"warning","value":"Study design is retrospective with a small case group (n=85); causal inferences about medication-specific QTc effects should not be drawn.","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"warning","value":"The Tisdale Risk Score was modified for outpatient use by excluding acute-illness items (e.g., sepsis, MI); this adapted version has not been formally validated.","value_numeric":null},{"paper_doi":"10.1093/fampra/cmag048","tag_type":"warning","value":"Zero QTP events occurred in the high-risk category (only 4 patients), making it impossible to assess the score's predictive value at the high-risk threshold.","value_numeric":null}],"summaries":{"what_studied":"A retrospective chart audit at two academic Family Medicine Clinics applied a modified Tisdale Risk Score to 85 primary care patients with paired pre- and post-pharmacotherapy ECGs (cases) and 184 controls without QTc-prolonging medications, to assess whether the score can guide prescribing and ECG monitoring decisions in outpatient primary care.","key_result":"QTc prolongation (QTc ≥500 ms or increase ≥60 ms from baseline) occurred in only 5/85 cases (5.9%), with no events in the high-risk Tisdale category; most cases were low risk (69.4%). The OR for QTP in moderate- vs. low-risk patients was 0.71 (95% CI: 0.07–6.98), which was non-significant. All 5 QTP events had additional risk factors, including amiodarone (3/5) or loop diuretics (2/5).","limitations":"- Only 85 of 486 patients had both pre- and post-pharmacotherapy ECGs, limiting statistical power to evaluate risk category associations.\n- The Tisdale score was developed and validated in inpatient cardiac settings; acute-illness items were excluded for this outpatient adaptation, but no primary care–specific tool exists.\n- Short-term QTc-prolonging agents (e.g., antibiotics) could not be evaluated due to lack of paired ECG data.","practice_takeaway":"Low-risk primary care patients starting psychotropics with low-to-moderate QTc effect who are not concurrently on other QTc-prolonging drugs or loop diuretics likely do not need routine ECG monitoring. Clinicians should remain alert when amiodarone, loop diuretics, or multiple QTc-prolonging agents are co-prescribed, as these were present in all observed QTP events."}},{"doi":"10.1016/j.hrtlng.2026.102836","pmid":"42160916","title":"Pharmacological burden and chemical phlebitis associated with peripheral venous catheters: A nested case-control study. Results of the national Flebitis Zero project","journal_title":"Heart & Lung","journal_issn":"0147-9563","published_at":"2026-05-20T00:00:00.000Z","url":"https://doi.org/10.1016/j.hrtlng.2026.102836","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-26T13:34:58.802Z","updated_at":"2026-05-26T13:34:58.802Z","tags":[{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"condition","value":"Chemical Phlebitis","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"condition","value":"Peripheral Venous Catheter Complications","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"generic","value":"amiodarone","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"generic","value":"caspofungin","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"generic","value":"ganciclovir","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"generic","value":"tobramycin","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"modality","value":"Aminoglycoside Antibiotic","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"modality","value":"Antiarrhythmic","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"modality","value":"Antifungal","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"modality","value":"Antiviral","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"modality","value":"Parenteral Nutrition","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"sample_size","value":"n=9409","value_numeric":9409},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"study_design","value":"Nested Case-Control Study","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"warning","value":"Data were collected in a single month (February 2023) across Spanish hospitals; seasonal, regional, and healthcare-system differences may limit generalizability.","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"warning","value":"Sample size for rare exposures (caspofungin, ganciclovir) was small, yielding very wide confidence intervals — interpret those specific aORs with caution.","value_numeric":null},{"paper_doi":"10.1016/j.hrtlng.2026.102836","tag_type":"warning","value":"The 'pharmacological burden' gradient lost consistency beyond two simultaneous products, which the authors note but do not fully explain — the dose-response relationship is not linear.","value_numeric":null}],"summaries":{"what_studied":"This nested case-control study within a prospective cohort across 93 Spanish hospitals examined which specific intravenous products and pharmacological burden levels independently increase the risk of chemical phlebitis in adult patients (≥18 years) receiving IV therapy via peripheral venous catheters (PIVCs) in February 2023.","key_result":"The highest phlebitis risks were linked to caspofungin (aOR=10.81), ganciclovir (aOR=8.14), amiodarone (aOR=4.14), tobramycin (aOR=3.71), and parenteral nutrition (aOR=2.93). Risk more than doubled with two simultaneous IV products vs. none (aOR=2.19; 95% CI: 1.82–2.65), though additional products beyond two did not show a consistent further increase.","limitations":"Single-month data collection limits generalizability across seasonal or practice variation. The exploratory design means causality cannot be confirmed. Rare exposures (e.g., caspofungin, ganciclovir) produced wide confidence intervals, reducing precision.","practice_takeaway":"Consider central or midline vascular access instead of a peripheral catheter for patients receiving high-risk irritants like caspofungin, ganciclovir, or amiodarone. Incorporate pharmacological risk scoring into vascular access decision algorithms, especially when two or more IV products are given simultaneously."}},{"doi":"10.1111/acem.70309","pmid":"42057249","title":"Initial 12 mg Versus 6 mg Adenosine for Supraventricular Tachycardia in the Emergency Department","journal_title":"Academic Emergency Medicine","journal_issn":"1069-6563","published_at":"2026-04-30T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13128986/","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-09","doi":"10.1111/acem.70309","days":"7","issn":"1069-6563","rank":"8","field":"Clinical Medicine","score":"2","category":"Emergency Medicine","categories":["Emergency Medicine"],"_categories":["Emergency Medicine"]},"pubmed":{"doi":"10.1111/acem.70309","title":"Initial 12 mg Versus 6 mg Adenosine for Supraventricular Tachycardia in the Emergency Department.","journal":"Academic emergency medicine : official journal of the Society for Academic Emergency Medicine","methods":"","results":"A total of 142 patients were analyzed (n = 71 per group). First-dose conversion was significantly higher with 12 mg compared with 6 mg (83.1% vs. 52.1%). In the PSM cohort (n = 104), the 12 mg dose maintained its superior efficacy (82.7% vs. 53.8%). The PSM-adjusted odds ratio for successful conversion was 4.12 (95% confidence interval [CI]: 1.85-9.14), with a number needed to treat (NNT) of 3.8 (95% CI: 2.5-8.3). SVT recurrence was numerically lower in the 12 mg group (1.4% vs. 9.9%). Adverse effects were similar between groups.","abstract":"$30","keywords":["adenosine","adverse effects","emergency department","sinus rhythm conversion","supraventricular tachycardia"],"pubmed_id":"42057249","conclusions":"","publication_date":"2026-04-30T00:00:00"},"crossref":{"DOI":"10.1111/acem.70309","URL":"https://doi.org/10.1111/acem.70309","ISSN":["1069-6563","1553-2712"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/acem.70309","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/acem.70309","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/acem.70309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"5","score":1,"title":["Initial 12 mg Versus 6 mg Adenosine for Supraventricular Tachycardia in the Emergency Department"],"author":[{"given":"Ekrem Taha","family":"Sert","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine Aksaray University Faculty of Medicine Aksaray Turkey"}]},{"given":"Kamil","family":"Kokulu","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Aksaray University Faculty of Medicine Aksaray Turkey"}]},{"given":"Oğuz","family":"Yürük","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Aksaray University Faculty of Medicine Aksaray Turkey"}]},{"given":"Emin Hüseyin","family":"Akar","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Aksaray University Faculty of Medicine Aksaray Turkey"}]},{"given":"Muhammed Ali","family":"Topuz","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Aksaray University Faculty of Medicine Aksaray Turkey"}]}],"issued":{"date-parts":[[2026,4,29]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"33","archive":["Portico"],"created":{"date-time":"2026-04-30T04:15:21Z","timestamp":1777522521000,"date-parts":[[2026,4,30]]},"indexed":{"date-time":"2026-05-04T02:24:42Z","timestamp":1777861482030,"date-parts":[[2026,5,4]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000,"date-parts":[[2026,4,29]]},"delay-in-days":0,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000,"date-parts":[[2026,4,29]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/acem.70309"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2026-03-15"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2026-04-20"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-04-29"}],"deposited":{"date-time":"2026-04-30T04:15:31Z","timestamp":1777522531000,"date-parts":[[2026,4,30]]},"issn-type":[{"type":"print","value":"1069-6563"},{"type":"electronic","value":"1553-2712"}],"published":{"date-parts":[[2026,4,29]]},"publisher":"Wiley","reference":[{"DOI":"10.1186/s12873-025-01288-8","key":"e_1_2_14_2_1","year":"2025","issue":null,"author":"Zou H.","volume":"25","first-page":"125","unstructured":null,"article-title":"Current Practices and Knowledge of Adenosine Administration for Paroxysmal Supraventricular Tachycardia: A Multi‐Province Survey in Chinese Emergency Departments","journal-title":"BMC Emergency Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1093/eurheartj/ehz467","key":"e_1_2_14_3_1","year":"2020","issue":null,"author":"Brugada J.","volume":"41","first-page":"655","unstructured":null,"article-title":"2019 ESC Guidelines for the Management of Patients With Supraventricular Tachycardia","journal-title":"European Heart Journal","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_14_4_1","year":"2016","issue":null,"author":"Page R. L.","volume":"133","first-page":"e506","unstructured":null,"article-title":"2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","journal-title":"Circulation","doi-asserted-by":null},{"DOI":"10.1016/j.ajem.2024.01.035","key":"e_1_2_14_5_1","year":"2024","issue":null,"author":"Xiao L.","volume":"78","first-page":"157","unstructured":null,"article-title":"Combined Modified Valsalva Maneuver With Adenosine Supraventricular Tachycardia: A Comparative Study","journal-title":"American Journal of Emergency Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1097/MEJ.0000000000001050","key":"e_1_2_14_6_1","year":"2023","issue":null,"author":"Alghadeer S. M.","volume":"30","first-page":"341","unstructured":null,"article-title":"Adenosine Response and Failure to Convert Paroxysmal Supraventricular Tachycardia in the Emergency Department","journal-title":"European Journal of Emergency Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajem.2024.08.044","key":"e_1_2_14_7_1","year":"2024","issue":null,"author":"Krug N.","volume":"85","first-page":"117","unstructured":null,"article-title":"Comparison of Initial Adenosine Dose Conversion Rate for Supraventricular Tachycardia in the Emergency Department","journal-title":"American Journal of Emergency Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1080/10903127.2025.2504521","key":"e_1_2_14_8_1","year":"2025","issue":null,"author":"Fernandez A. R.","volume":"1","first-page":"1","unstructured":null,"article-title":"Comparing Prehospital Adenosine Initial Dosing of 6 mg Versus 12 mg for Presumed Paroxysmal Supraventricular Tachycardia (PSVT)","journal-title":"Prehospital Emergency Care","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(15)61485-4","key":"e_1_2_14_9_1","year":"2015","issue":"10005","author":"Appelboam A.","volume":"386","first-page":"1747","unstructured":null,"article-title":"Postural Modification to the Standard Valsalva Manoeuvre for Emergency Treatment of Supraventricular Tachycardias (REVERT): A Randomised Controlled Trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jemermed.2025.05.020","key":"e_1_2_14_10_1","year":"2025","issue":null,"author":"Lee C. A.","volume":"75","first-page":"55","unstructured":null,"article-title":"Adenosine Versus Fixed‐Dose Intravenous Bolus Diltiazem on Reversing Supraventricular Tachycardia in the Emergency Department: A Multi‐Center Cohort Study","journal-title":"Journal of Emergency Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jemermed.2025.02.006","key":"e_1_2_14_11_1","year":"2025","issue":null,"author":"Sert E. T.","volume":"74","first-page":"54","unstructured":null,"article-title":"Predictive Value of Ionized Calcium Level for Sinus Rhythm Conversion in Adenosine Treatment for Paroxysmal Supraventricular Tachycardia","journal-title":"Journal of Emergency Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1080/00273171.2011.568786","key":"e_1_2_14_12_1","year":"2011","issue":"3","author":"Austin P. C.","volume":"46","first-page":"399","unstructured":null,"article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","journal-title":"Multivariate Behavioral Research","doi-asserted-by":"crossref"},{"DOI":"10.1214/09-STS313","key":"e_1_2_14_13_1","year":"2010","issue":"1","author":"Stuart E. A.","volume":"25","first-page":"1","unstructured":null,"article-title":"Matching Methods for Causal Inference: A Review and a Look Forward","journal-title":"Statistical Science","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_14_14_1","year":"2017","issue":"10","author":"Alabed S.","volume":"10","first-page":null,"unstructured":null,"article-title":"Adenosine Versus Intravenous Calcium Channel Antagonists for Supraventricular Tachycardia","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":"10.1016/j.ajem.2025.12.016","key":"e_1_2_14_15_1","year":"2025","issue":null,"author":"Şirin İ.","volume":"101","first-page":"22","unstructured":null,"article-title":"Response Heterogeneity in Patients With Vagal‐Refractory Paroxysmal Supraventricular Tachycardia Treated With Adenosine: A Retrospective Study","journal-title":"American Journal of Emergency Medicine","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/acem.70309"],"article-number":"e70309","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Academic Emergency Medicine"],"published-print":{"date-parts":[[2026,5]]},"reference-count":14,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,29]]},"references-count":14,"short-container-title":["Academic Emergency Medicine"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/acem.70309","is_oa":true,"title":"Initial 12 mg Versus 6 mg Adenosine for Supraventricular Tachycardia in the Emergency Department","updated":"2026-05-05T11:59:32+00:00","published_date":"2026-04-29","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13128986/","pmh_id":"oai:pubmedcentral.nih.gov:13128986","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13128986/"}}},"created_at":"2026-05-10T13:20:43.213Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1111/acem.70309","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"category","value":"Emergency Medicine","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"condition","value":"Supraventricular Tachycardia","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"generic","value":"adenosine","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"modality","value":"Antiarrhythmic","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"sample_size","value":"n=142","value_numeric":142},{"paper_doi":"10.1111/acem.70309","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"study_design","value":"Prospective Observational Study","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"warning","value":"Propensity score matching reduced the cohort from 142 to 104 patients, slightly limiting precision (wide CIs noted for primary outcome).","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"warning","value":"SVT subtype classification relied on 12-lead ECG without invasive electrophysiology; some cases may have been atrial tachycardia or spontaneously terminating arrhythmias.","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"warning","value":"The dose allocation was based on physician discretion, introducing potential selection bias not fully correctable by PSM.","value_numeric":null},{"paper_doi":"10.1111/acem.70309","tag_type":"warning","value":"The study is non-randomized and single-center; the 'practice_changing' flag reflects a clinically meaningful effect size but should be interpreted cautiously until confirmed by an RCT.","value_numeric":null}],"summaries":{"what_studied":"This prospective observational study compared an initial 12 mg vs. 6 mg IV adenosine dose for first-dose sinus rhythm conversion in 142 hemodynamically stable adult ED patients with ECG-confirmed SVT (AVNRT/AVRT), conducted February 2025–January 2026 at a single tertiary-care ED in Turkey.","key_result":"First-dose conversion was 83.1% with 12 mg vs. 52.1% with 6 mg (absolute difference 31%; PSM-adjusted OR 4.12, 95% CI 1.85–9.14; NNT ~4). SVT recurrence during the ED stay was numerically lower with 12 mg (1.4% vs. 9.9%), though not statistically significant. Adverse effects (chest tightness ~85–89%, flushing, dyspnea, etc.) were similar between groups.","limitations":"- Non-randomized observational design with physician-discretion dosing; residual confounding cannot be excluded despite PSM.\n- Single-center study at one tertiary ED in Turkey, limiting generalizability.\n- SVT recurrence and adverse effects were only assessed during the ED stay; no long-term follow-up.","practice_takeaway":"Starting with 12 mg adenosine instead of 6 mg roughly doubled first-dose conversion rates (83% vs. 52%) with no increase in adverse effects — about 1 in 4 patients was spared a repeat dose. Clinicians managing stable SVT in the ED may consider 12 mg as the initial dose, pending confirmation in randomized trials."}},{"doi":"10.1097/pec.0000000000003556","pmid":"42050967","title":"Letter to the Editor Regarding Comparison of Adenosine Administration Utilizing a Single-Syringe Versus a Double-Syringe Method in a Simulated Pediatric Patient; Authors Response","journal_title":"Pediatric Emergency Care","journal_issn":"0749-5161","published_at":"2026-04-29T00:00:00.000Z","url":"https://doi.org/10.1097/pec.0000000000003556","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:50:47.853Z","updated_at":"2026-05-07T22:50:47.853Z","tags":[{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"category","value":"Emergency Medicine","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"condition","value":"Supraventricular Tachycardia","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"generic","value":"adenosine","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"modality","value":"Antiarrhythmic","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"study_design","value":"Letter to the Editor / Author Response","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"warning","value":"Study design label is approximate; letters/author responses do not fit standard evidence hierarchy levels.","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"warning","value":"The underlying study being discussed (single- vs double-syringe adenosine in a simulated pediatric patient) is a separate publication; summaries here reflect only the correspondence, not that study's findings.","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003556","tag_type":"warning","value":"This paper is a letter to the editor and author response, not a primary research article — no original data, sample size, or outcomes are available to extract.","value_numeric":null}],"summaries":{"what_studied":"This is an authors' response to a letter to the editor regarding a study comparing single-syringe versus double-syringe methods of adenosine administration in a simulated pediatric patient model.","limitations":"As a letter/author response, this document contains no primary data, outcomes, or statistical results of its own."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Antiarrhythmic"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Antiarrhythmic"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Antiarrhythmic"}}}]]

Papers